Ustekinumab is a human monoclonal antibody used to treat psoriasis, psoraitic arthritis and Crohn’s disease.
- It blocks interleukin IL-12 and IL-23, which help activate certain T-cells, by binding to the p-40 subunit of both IL-12 and IL-23 so that they subsequently cannot bind to their receptors.
- It is administered through subcutaneous injection every 8 weeks.
- In 2016, it sold €572 million in Europe.
- It has an immunogenicity rate of 1-11%.